HTI-1511 is a novel antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) to potentially treat solid tumors, including those with drug-resistant mutations. HTI-1511 was engineered to bind to EGFR at the low pH of the tumor microenvironment while decreasing or attenuating binding at the neutral pH of skin. As a result of encouraging preclinical findings for this targeted therapy and its supportive safety profile, HTI-1511 has been selected for further study as an investigational new drug candidate (Pre-IND).

HTI-1511 has been developed as a next-generation ADC with a potent cytotoxin called monomethyl auristatin E to treat EGFR-positive tumors, including those with KRAS and BRAF mutations. In preclinical studies, HTI-1511 demonstrated tumor growth inhibition or regression in colon, lung and cholangiocarcinoma models, including patient-derived xenograft (PDx) models with known KRAS and BRAF mutations.


You are now leaving Halozyme is not responsible for or endorses the content of the linked site.